IRECIST Evaluation’s Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab
Ontology highlight
ABSTRACT: This is a non-randomized study, open label phase II study. The purpose of this study is to evaluate disease control rate (DCR) by RECIST and iRECIST at 12 weeks.
Evaluation of RECIST and iRECIST will be done in each center in order to choose the optimal therapy (Assessment by Investigators).
A centralized evaluation of RECIST and iRECIST, will be organized in Saint-Antoine.
DISEASE(S): Neoplasm Metastasis,Metastatic Cancer Colorectal,Colorectal Neoplasms
PROVIDER: 2259500 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA